Press Releases

Press Releases

May 11, 2020
CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturing NVX ‑ CoV2373 Phase I trial initiating in May with preliminary results in July NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial Company to host conference call today at...
Mar 11, 2020
NanoFlu top-line data from Phase 3 clinical trial expected by the end of this month Novavax awarded CEPI funding to support COVID-19 vaccine program COVID-19 Phase 1 clinical trial expected to initiate in late spring of 2020 Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md....
Mar 10, 2020
CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1 Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials Phase 1 clinical trial expected to initiate in late spring of 2020 GAITHERSBURG, Md....
Displaying 21 - 30 of 180